1. Scott, NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev 2006; 58: 358–376.
Google Scholar | Crossref | Medline | ISI2. Kim, MS, Dean, LS. In-stent restenosis. Cardiovasc Ther 2011; 29: 190–198.
Google Scholar | Crossref | Medline | ISI3. Blum, A, Schneider, DJ, Sobel, BE, et al. Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol 2004; 94: 1420–1423.
Google Scholar | Crossref | Medline4. Li, JJ, Fang, CH, Jiang, H, et al. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal stenosis. Clin Chim Acta 2004; 350: 115–121.
Google Scholar | Crossref | Medline5. Li, JJ, Li, J, Nan, JL, et al. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects. Med Hypotheses 2007; 69: 1004–1009.
Google Scholar | Crossref | Medline | ISI6. Ikonomidis, I, Michalakeas, CA, Lekakis, J, et al. The role of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) in cardiovascular disease. Rev Recent Clin Trials 2011; 6: 108–113.
Google Scholar | Crossref | Medline7. Santoso, A, Kaniawati, M, Bakri, S, et al. Secretory phospholipase A2 is associated with the odds of acute coronary syndromes through elevation of serum amyloid-A protein. Int J Angiol 2013; 22: 49–54.
Google Scholar | Crossref | Medline8. Garg, PK, Norby, FL, Polfus, LM, et al. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: findings from the atherosclerosis risk in communities study (ARIC). Atherosclerosis 2018; 268: 12–18.
Google Scholar | Crossref | Medline9. Maiolino, G, Bisogni, V, Rossitto, G, et al. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol 2015; 7: 609–620.
Google Scholar | Crossref | Medline10. Zheng, D, Zeng, F, Cai, A, et al. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis 2014; 13: 41.
Google Scholar | Crossref | Medline11. Moldoveanu, E, Mut-Vitcu, B, Tanaseanu, GR, et al. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem 2008; 41: 1429–1433.
Google Scholar | Crossref | Medline12. Chen, QR, You, W, Wu, ZM, et al. Relationship between serum lipoprotein-associated phospholipase A2 and intra-stent restenosis after drug-eluting stent implantation in elderly patients with coronary heart disease [Meeting Abstract]. J Am Geriatr Soc 2018; 66: S452–S452.
Google Scholar | Medline13. Dangas, GD, Claessen, BE, Caixeta, A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897–1907.
Google Scholar | Crossref | Medline | ISI14. Kastrati, A, Schomig, A, Elezi, S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428–1436.
Google Scholar | Crossref | Medline | ISI15. Ivens, K, Gradaus, F, Heering, P, et al. Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting. Int Urol Nephrol 2001; 32: 717–723.
Google Scholar | Crossref | Medline16. Zhu, ss, Wu, zk, Hu, ym. Relationship between plasma lipoprotein associated phospholipase A2 and coronary in-stent restenosis after percutaneous coronary intervention. Tianjin Med J 2018; 46: 746–750.
Google Scholar17. Gu, cf, Liu, jx, Zheng, qk, et al. Relationship between serum uric acid and coronaryin in-stent restenosis in middle-aged and old patients with coronary heart disease. J Clin Intern Med 2017; 34: 242–245.
Google Scholar18. Palmaz, JC, Bailey, S, Marton, D, et al. Influence of stent design and material composition on procedure outcome. J Vasc Surg 2002; 36: 1031–1039.
Google Scholar | Crossref | Medline | ISI19. Stefanini, GG, Holmes, DR Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254–265.
Google Scholar | Crossref | Medline | ISI20. Kimura, T, Yokoi, H, Nakagawa, Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334: 561–566.
Google Scholar | Crossref | Medline | ISI21. Schatz, RA, Palmaz, JC, Tio, FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation 1987; 76: 450–457.
Google Scholar | Crossref | Medline | ISI22. Komatsu, R, Ueda, M, Naruko, T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224–233.
Google Scholar | Crossref | Medline | ISI23. Park, DW, Hong, MK, Mintz, GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late “catch-up” phenomenon from ASPECT study. J Am Coll Cardiol 2006; 48: 2432–2439.
Google Scholar | Crossref | Medline24. Nakagawa, Y, Kimura, T, Morimoto, T, et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher registry). Am J Cardiol 2010; 106: 329–336.
Google Scholar | Crossref | Medline | ISI25. Aoki, J, Colombo, A, Dudek, D, et al. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005; 112: 3876–3883.
Google Scholar | Crossref | Medline26. Kowalski, J, Kośmider, M, Pawlicki, L, et al. Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. Int J Cardiol 1997; 58: 229–240.
Google Scholar | Crossref | Medline | ISI27. Serrano, CV, Ramires, JA, Venturinelli, M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29: 1276–1283.
Google Scholar | Crossref | Medline | ISI28. Boffa, MB, Marcovina, SM, Koschinsky, ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004; 37: 333–343.
Google Scholar | Crossref | Medline | ISI29. Tsimikas, S, Tsironis, LD, Tselepis, AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2094–2099.
Google Scholar | Crossref | Medline30. Garg, PK, McClelland, RL, Jenny, NS, et al. Association of lipoprotein-associated phospholipase A(2) and endothelial function in the multi-ethnic study of atherosclerosis (MESA). Vasc Med 2011; 16: 247–252.
Google Scholar | SAGE Journals | ISI31. Nakazawa, G, Otsuka, F, Nakano, M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314–1322.
Google Scholar | Crossref | Medline | ISI32. Higo, T, Ueda, Y, Oyabu, J, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging 2009; 2: 616–624.
Google Scholar | Crossref | Medline33. Asano, K, Okamoto, S, Fukunaga, K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261: 511–514.
Google Scholar | Crossref | Medline | ISI34. Stafforini, DM, Elstad, MR, McIntyre, TM, et al. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990; 265: 9682–9687.
Google Scholar | Crossref | Medline35. Lp, P, Thompson, A, Gao, P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536–1544.
Google Scholar | Crossref | Medline36. Packard, CJ, O’Reilly, DS, Caslake, MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med 2000; 343: 1148–1155.
Google Scholar | Crossref | Medline | ISI37. Silva, IT, Mello, AP, Damasceno, NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): a review. Lipids Health Dis 2011; 10: 170–101.
Google Scholar | Crossref